atorvastatin vs glecaprevir/pibrentasvir
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of atorvastatin and glecaprevir/pibrentasvir. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
minor Known Drug Interaction
HMG-CoA Reductase Inhibitors: Atorvastatin Lovastatin Simvastatin ↑ atorvastatin ↑ lovastatin ↑ simvastatin Coadministration may increase the concentration of atorvastatin, lovastatin, and simvastatin.
Lipitor
Mavyret
Atorvastatin is a drug that lowers cholesterol and reduces the risk of heart problems and stroke. It belongs to a class of drugs called statins.
Mavyret is a medicine used to treat hepatitis C (HCV) in adults and children 3 years and older. It contains two drugs, glecaprevir and pibrentasvir, that work together to stop the virus from multiplying.
Atorvastatin is used to lower bad cholesterol (LDL) and triglycerides in your blood. It can help prevent heart attacks, strokes, and the need for heart procedures in adults with heart disease or risk factors for it. It is also used in children 10 years and older with certain inherited cholesterol problems.
Mavyret treats hepatitis C virus (HCV) genotypes 1, 2, 3, 4, 5, or 6. It can be used in people without cirrhosis or with compensated cirrhosis. Mavyret can also treat genotype 1 in people who have already been treated with certain other HCV medicines.
Atorvastatin works by blocking a substance your body needs to make cholesterol. This helps to lower the amount of cholesterol in your blood. Lowering cholesterol can help prevent heart disease.
Mavyret contains glecaprevir and pibrentasvir. Glecaprevir blocks a protein called NS3/4A protease that the virus needs to multiply. Pibrentasvir blocks a protein called NS5A, also needed for the virus to multiply. By blocking these proteins, Mavyret stops the hepatitis C virus from spreading in your body.
- • Common cold symptoms
- • Joint pain
- • Diarrhea
- • Pain in arms or legs
- • Urinary tract infection
- • Headache
- • Feeling tired
- • Nausea
- Fatigue 13,812
- Nausea 12,425
- Type 2 Diabetes Mellitus 11,244
- Diarrhoea 11,037
- Dyspnoea 11,029
- Feeling tired 2,561
- Headache 2,203
- Nausea 1,125
- Itching 653
- Diarrhea 477
Atorvastatin can cause muscle problems, including muscle pain, tenderness, or weakness. In rare cases, this can lead to serious kidney damage. Tell your doctor right away if you have unexplained muscle pain, tenderness, or weakness, especially if you also have a fever or feel sick. Atorvastatin can also cause liver problems. Your doctor may do blood tests to check your liver before you start taking atorvastatin and while you are taking it.
Mavyret can cause hepatitis B to become active again if you have had it in the past. This can cause serious liver problems, including liver failure and death. Your doctor will test you for hepatitis B before you start Mavyret. They will also monitor you during and after treatment.
Atorvastatin can harm an unborn baby. You should not take atorvastatin if you are pregnant or planning to become pregnant. It is also not recommended to breastfeed while taking atorvastatin.
It is not known if Mavyret will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. It is also not known if Mavyret passes into breast milk. Talk to your doctor about the best way to feed your baby if you are taking Mavyret.
Also Compare, Nearby Drugs
Compare atorvastatin with
How to Read This atorvastatin vs glecaprevir/pibrentasvir Comparison
atorvastatin is classified in the HMG-CoA Reductase Inhibitor (Statin) drug class, while glecaprevir/pibrentasvir sits within the NS3/4A/NS5A Inhibitor (HCV) class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, atorvastatin has 59,547 submissions while glecaprevir/pibrentasvir has 7,019. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known minor interaction flagged in FDA labeling, attributed to this combination can cause the amount of atorvastatin in your blood to increase.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for atorvastatin or glecaprevir/pibrentasvir.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.